GRID DYNAMICS HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GRID DYNAMICS HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $111.28M | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | $118.33M | Mar 5, 2021 |
| FY2020 | Dec 31, 2018 | $91.87M | Mar 5, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $411.83M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $350.57M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $312.91M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $310.48M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $211.28M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $111.28M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $118.33M | Mar 3, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.35M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $127.01M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $113.15M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $120.59M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $87.73M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $41.62M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $48.24M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $39.31M | Mar 5, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.67M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $4.04M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($1.77M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($29.21M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($7.70M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($12.60M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $10.81M | Mar 3, 2022 |
| FY2019 | Dec 31, 2018 | $615.4K | Mar 4, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.90M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($2.11M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | ($5.58M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | ($21.01M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $50.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($15.45M) | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $15.63M | Mar 3, 2022 |
| FY2019 | Dec 31, 2018 | ($325.7K) | Mar 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.67M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $18.35M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $14.74M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $15.77M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $8.46M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $9.31M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $4.35M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $2.64M | Mar 5, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $37.71M | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | $21.32M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $325.7K | Mar 4, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.60M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $30.20M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $41.09M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $31.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $17.97M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $5.93M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $12.53M | Mar 3, 2022 |
| FY2019 | Dec 31, 2018 | ($303.7K) | Mar 4, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.33M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $11.77M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $7.87M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $6.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.72M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.25M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $2.81M | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | $3.08M | Mar 5, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $612.89M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $592.19M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $435.17M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $411.15M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $256.72M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $167.14M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $71.53M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $222.36M | Mar 4, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $70.82M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $74.36M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $52.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $48.10M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $29.67M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $15.41M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $8.30M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $8.15M | Mar 4, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $542.07M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $517.83M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $382.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $363.04M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $227.05M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $151.72M | Mar 3, 2022 |
| FY2021 | Dec 31, 2019 | $54.04M | Mar 3, 2022 |
| FY2021 | Dec 31, 2018 | $33.38M | Mar 3, 2022 |
| FY2020 | Dec 31, 2017 | $24.40M | Mar 5, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.36M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $83.41M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $53.87M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $45.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $35.96M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $14.69M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $0 | Mar 3, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.18M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($11.85M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($15.89M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.12M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $15.09M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $22.79M | Mar 3, 2022 |
| FY2019 | Dec 31, 2019 | ($2.71M) | Mar 4, 2020 |
| FY2019 | Dec 31, 2018 | $615.4K | Mar 4, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $342.06M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $334.66M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $257.23M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $256.73M | Feb 27, 2025 |
| FY2022 | Dec 31, 2021 | $144.36M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $112.75M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | $42.19M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $1.01M | Mar 4, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 5, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 3, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 5, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 84.84M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 83.61M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 75.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 74.16M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 66.85M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 50.88M | Mar 3, 2022 |
| FY2020 | Dec 31, 2019 | 21.64M | Mar 5, 2021 |